Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors

Summary

This is a FIH, open-label, Phase I dose-escalation study of ADG116 in subjects with advanced/metastatic solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. ADG 116 administered intravenously (IV) over a period of 60-90 minutes. The study planned to treated 42 patients.

Timeline

Start

2019-08-29

Primary completion

2021-04-27

Completion

2021-04-27

Drugs

Indications